{"id":23783,"date":"2022-12-07T17:24:00","date_gmt":"2022-12-07T09:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23783"},"modified":"2025-01-29T17:29:22","modified_gmt":"2025-01-29T09:29:22","slug":"akesos-ivonescimab-secures-record-breaking-out-license-deal-with-summit-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23783","title":{"rendered":"Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics"},"content":{"rendered":"\n

A new bar was set for the most valuable out-license deal struck by a China-based company, as Akeso Inc., (HKG: 9926<\/a>) handed US firm Summit Therapeutics Inc., (NASDAQ: SMMT<\/a>) exclusive development and commercialization rights to the bispecific antibody (BsAb) ivonescimab. The deal covers the territories of the United States, Canada, Europe, and Japan. Akeso retains development and commercialization rights to the drug in all other territories, alongside co-branding brand equity in said regions.<\/p>\n\n\n\n

Deal Terms and Financials<\/strong>
Summit will make a USD 500 million upfront payment and is committed to USD 4.5 billion in regulatory and commercial milestone payments, alongside low double-digit royalties on net sales. This far outstrips the previous biggest out-license deal struck by a China-based firm, BeiGene\u2019s USD 2.89 billion license of a TIGIT inhibitor to Novartis in December last year. Alongside the deal, Akeso founder and CEO Dr. Michelle Xia will be appointed to Summit\u2019s board of directors.<\/p>\n\n\n\n

Ivonescimab: Mechanism and Development<\/strong>
Ivonescimab (AK112 \/ SMT112) is a novel, potential first-in-class bispecific antibody that combines a dual mechanism of immunotherapy via blockade of programmed death-1 (PD-1) with anti-angiogenesis benefits from inhibition of anti-vascular endothelial growth factor (VEGF). The drug has reached the Phase III stage, the most advanced of and PD-1\/VEGF BsAb under development globally. No PD-1-based BsAbs have so far been approved in the US or Europe.<\/p>\n\n\n\n

Clinical Trials and Future Plans<\/strong>
Akeso has initiated a Phase III head-to-head study for ivonescimab in first-line PD-L1-positive non-small cell lung cancer (NSCLC) compared with pembrolizumab, and another Phase III for ivonescimab combined with chemotherapy vs. chemotherapy alone in advanced NSCLC with epidermal growth factor receptor (EGFR) mutations resistant to EGFR tyrosine kinase inhibitor (TKI). According to clinicaltrials.gov, 10 clinical trials for the drug are in China while 1 Phase I study was held in Australia.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new bar was set for the most valuable out-license deal struck by a China-based…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[360,850,28,1181,18,712],"class_list":["post-23783","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-akeso-biopharma","tag-hkg-9926","tag-multi-specific-antibodies","tag-nasdaq-smmt","tag-pd-1-l1","tag-summit-therapeutics"],"yoast_head":"\nAkeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"A new bar was set for the most valuable out-license deal struck by a China-based company, as Akeso Inc., (HKG: 9926) handed US firm Summit Therapeutics Inc., (NASDAQ: SMMT) exclusive development and commercialization rights to the bispecific antibody (BsAb) ivonescimab. The deal covers the territories of the United States, Canada, Europe, and Japan. Akeso retains development and commercialization rights to the drug in all other territories, alongside co-branding brand equity in said regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-07T09:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T09:29:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics\",\"datePublished\":\"2022-12-07T09:24:00+00:00\",\"dateModified\":\"2025-01-29T09:29:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783\"},\"wordCount\":311,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Akeso Biopharma\",\"HKG: 9926\",\"Multi-specific antibodies\",\"NASDAQ: SMMT\",\"PD-1\\\/L1\",\"Summit Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23783#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23783\",\"name\":\"Akeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-07T09:24:00+00:00\",\"dateModified\":\"2025-01-29T09:29:22+00:00\",\"description\":\"A new bar was set for the most valuable out-license deal struck by a China-based company, as Akeso Inc., (HKG: 9926) handed US firm Summit Therapeutics Inc., (NASDAQ: SMMT) exclusive development and commercialization rights to the bispecific antibody (BsAb) ivonescimab. The deal covers the territories of the United States, Canada, Europe, and Japan. Akeso retains development and commercialization rights to the drug in all other territories, alongside co-branding brand equity in said regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23783\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics - Insight, China's Pharmaceutical Industry","description":"A new bar was set for the most valuable out-license deal struck by a China-based company, as Akeso Inc., (HKG: 9926) handed US firm Summit Therapeutics Inc., (NASDAQ: SMMT) exclusive development and commercialization rights to the bispecific antibody (BsAb) ivonescimab. The deal covers the territories of the United States, Canada, Europe, and Japan. Akeso retains development and commercialization rights to the drug in all other territories, alongside co-branding brand equity in said regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23783","og_locale":"en_US","og_type":"article","og_title":"Akeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23783","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-07T09:24:00+00:00","article_modified_time":"2025-01-29T09:29:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics","datePublished":"2022-12-07T09:24:00+00:00","dateModified":"2025-01-29T09:29:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23783"},"wordCount":311,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Akeso Biopharma","HKG: 9926","Multi-specific antibodies","NASDAQ: SMMT","PD-1\/L1","Summit Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23783#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23783","url":"https:\/\/flcube.com\/?p=23783","name":"Akeso's Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-07T09:24:00+00:00","dateModified":"2025-01-29T09:29:22+00:00","description":"A new bar was set for the most valuable out-license deal struck by a China-based company, as Akeso Inc., (HKG: 9926) handed US firm Summit Therapeutics Inc., (NASDAQ: SMMT) exclusive development and commercialization rights to the bispecific antibody (BsAb) ivonescimab. The deal covers the territories of the United States, Canada, Europe, and Japan. Akeso retains development and commercialization rights to the drug in all other territories, alongside co-branding brand equity in said regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23783"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23783\/revisions"}],"predecessor-version":[{"id":23784,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23783\/revisions\/23784"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}